New dosing strategy for MS drug ublituximab under study in 800-Patient trial

NCT ID NCT05877963

Recruiting now Disease control Sponsor: TG Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This Phase 3 trial is testing a modified dosing schedule of ublituximab (BRIUMVI) in 800 people with relapsing multiple sclerosis. The study has three parts: one open-label part to see if the new regimen reduces brain lesions, a placebo-controlled part to measure drug levels, and another open-label part for those who had a poor response to prior anti-CD20 therapy. The goal is to find a safer or more effective way to control MS relapses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ublituximab (BRIUMVI)
What this could lead to: If successful, this could offer a more effective or convenient dosing schedule for ublituximab to control relapsing multiple sclerosis.
What could go wrong: This is a Phase 3 study, but results may not confirm benefit over existing treatments. Infusion-related reactions and other side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING MULTIPLE SCLEROSIS

Contacts and locations

Locations

TG Investigational Site
RECRUITING

Fort Collins, Colorado, 80528, United States
TG Investigational Site
RECRUITING

Farmington, Michigan, 48334, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Birmingham, Alabama, 35209, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Cullman, Alabama, 35058, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Orange, California, 92697, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Washington D.C., District of Columbia, 20007, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Tampa, Florida, 33612, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Savannah, Georgia, 31406, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Chicago, Illinois, 60612, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Indianapolis, Indiana, 46256, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Iowa City, Iowa, 52242, United States
TG Therapeutics Investigational Trial Site
COMPLETED

Overland Park, Kansas, 66212, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Lutherville, Maryland, 21093, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Boston, Massachusetts, 00002, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Foxborough, Massachusetts, 02035, United States
TG Therapeutics Investigational Trial Site
RECRUITING

North Worcester, Massachusetts, 01655, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Wellesley, Massachusetts, 02481uni, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Golden Valley, Minnesota, 55422, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Plymouth, Minnesota, 55446, United States
TG Therapeutics Investigational Trial Site
RECRUITING

St Louis, Missouri, 63131, United States
TG Therapeutics Investigational Trial Site
RECRUITING

New York, New York, 10025, United States
TG Therapeutics Investigational Trial Site
RECRUITING

New York, New York, 11021, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Raleigh, North Carolina, 27607, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Cleveland, Ohio, 44195, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Dayton, Ohio, 45417, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Greenville, South Carolina, 29605, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Knoxville, Tennessee, 37922, United States
TG Therapeutics Investigational Trial Site
COMPLETED

Houston, Texas, 77030, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Salt Lake City, Utah, 84103, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Vienna, Virginia, 22182, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Kirkland, Washington, 98034, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Seattle, Washington, 98109, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Spokane, Washington, 99208, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Milwaukee, Wisconsin, 53226, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Bydgoszcz, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Katowice, 40-555, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Katowice, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Kielce, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Krakow, 31-826, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Lodz, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Olsztyn, 10-561, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Poznan, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Warsaw, 04-141, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Zabrze, Poland
TG Therapeutics Investigational Trial Site
RECRUITING

Żory, 44-240, Poland
TG Therapeutics Investigational Trial SiteCharlotte
RECRUITING

Charlotte, North Carolina, 28204, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.